Ovarian highlights from ESMO 2019

Comment: Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC

More ovarian cancer patients benefit from maintenance combined targeted therapy

Comment: PARP inhibitor olaparib plus bevacizumab in women with ovarian cancer

Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC

Nivolumab plus ipilimumab combination offers chemotherapy-free option for advanced NSCLC

Comment: Osimertinib for EGFR-mutation positive NSCLC

PARP inhibitor olaparib added to bevacizumab benefits women with ovarian cancer with and without a BRCA mutation

Comment: Nivolumab plus ipilimumab combination for advanced NSCLC

Real-world use of carfilzomib in relapsed multiple myeloma patients with pre-existing cardiovascular comorbidities

Comparative effectiveness of lenalidomide, bortezomib, and their combinations for elderly myeloma patients

Synthesis, preclinical analysis, and first-inhuman phase I imaging of 89Zr-DFOdaratumumab for CD38 targeted imaging of myeloma